Too Old for Surgery? A Case Report of an Octogenarian Patient With Locally Advanced Lung Cancer Achieving Long-Term Survival via Bilobectomy Followed by Adjuvant Targeted Therapy

IF 2.5 Q4 ONCOLOGY
Cancer reports Pub Date : 2026-08-10 DOI:10.1002/cnr2.70652
Han-Yu Deng, Jia-Hao Li, Xiao-Jun Tang, Qinghua Zhou
{"title":"Too Old for Surgery? A Case Report of an Octogenarian Patient With Locally Advanced Lung Cancer Achieving Long-Term Survival via Bilobectomy Followed by Adjuvant Targeted Therapy","authors":"Han-Yu Deng,&nbsp;Jia-Hao Li,&nbsp;Xiao-Jun Tang,&nbsp;Qinghua Zhou","doi":"10.1002/cnr2.70652","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>An increasing number of octogenarian patients are being diagnosed with lung cancer, but they are less likely to receive surgery because of fragility. As a result, the optimal management of lung cancer in octogenarians remains unclear. Here we report a case of an octogenarian patient with locally advanced non-small-cell lung cancer (NSCLC) who achieved long-term survival via surgery followed by adjuvant targeted therapy.</p>\n </section>\n \n <section>\n \n <h3> Case</h3>\n \n <p>An 82-year-old male patient was admitted to our center for lung cancer surgery in April 2020 at West China Hospital, Sichuan University. He was clinically diagnosed with cT2N1M0(cIIB, AJCC 8th edition) lung cancer in the right lower lobe. Because of his good cardiopulmonary function without comorbidities, the patient was scheduled for thoracoscopic surgery. However, due to tumor invasion into the middle lobe and dense adhesions to the bronchus and vessels, the patient underwent conversion to open thoracotomy and finally received bilobectomy with systematic lymph node dissection. The patient recovered uneventfully and was discharged on postoperative day 5. After surgery, the patient was pathologically diagnosed with pT3N2M0(pIIIB) lung adenocarcinoma harboring an EGFR L858R gene mutation and began adjuvant icotinib. The patient progressed with multiple pulmonary metastasis at 13 months after starting icotinib and his liquid biopsy revealed a T790M mutation; he began treatment with the third-generation EGFR-TKI aumolertinib. In the last follow-up in December 2025, the patient remained on aumolertinib therapy and remained alive without progression.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Age alone is not a contraindication for lung cancer surgery and octogenarian patients may tolerate surgical resection following careful preoperative evaluation. Adjuvant targeted therapy may prolong survival in octogenarian lung cancer patients harboring oncogenic driving gene mutation after surgery.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 8","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70652","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70652","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

An increasing number of octogenarian patients are being diagnosed with lung cancer, but they are less likely to receive surgery because of fragility. As a result, the optimal management of lung cancer in octogenarians remains unclear. Here we report a case of an octogenarian patient with locally advanced non-small-cell lung cancer (NSCLC) who achieved long-term survival via surgery followed by adjuvant targeted therapy.

Case

An 82-year-old male patient was admitted to our center for lung cancer surgery in April 2020 at West China Hospital, Sichuan University. He was clinically diagnosed with cT2N1M0(cIIB, AJCC 8th edition) lung cancer in the right lower lobe. Because of his good cardiopulmonary function without comorbidities, the patient was scheduled for thoracoscopic surgery. However, due to tumor invasion into the middle lobe and dense adhesions to the bronchus and vessels, the patient underwent conversion to open thoracotomy and finally received bilobectomy with systematic lymph node dissection. The patient recovered uneventfully and was discharged on postoperative day 5. After surgery, the patient was pathologically diagnosed with pT3N2M0(pIIIB) lung adenocarcinoma harboring an EGFR L858R gene mutation and began adjuvant icotinib. The patient progressed with multiple pulmonary metastasis at 13 months after starting icotinib and his liquid biopsy revealed a T790M mutation; he began treatment with the third-generation EGFR-TKI aumolertinib. In the last follow-up in December 2025, the patient remained on aumolertinib therapy and remained alive without progression.

Conclusion

Age alone is not a contraindication for lung cancer surgery and octogenarian patients may tolerate surgical resection following careful preoperative evaluation. Adjuvant targeted therapy may prolong survival in octogenarian lung cancer patients harboring oncogenic driving gene mutation after surgery.

年纪太大,不适合做手术?80岁高龄局部晚期肺癌患者经胆管切除术后辅助靶向治疗获得长期生存的1例报告。
背景:越来越多的80多岁的患者被诊断为肺癌,但他们不太可能接受手术,因为脆弱。因此,八十多岁肺癌的最佳治疗方法仍不清楚。在这里,我们报告了一例八十多岁的局部晚期非小细胞肺癌(NSCLC)患者,通过手术和辅助靶向治疗获得了长期生存。病例:一名82岁男性患者于2020年4月在四川大学华西医院我中心行肺癌手术。临床诊断为右下叶cT2N1M0(cIIB, AJCC第8版)肺癌。由于患者心肺功能良好,无合并症,故安排行胸腔镜手术。但由于肿瘤侵袭中叶,且与支气管及血管粘连紧密,患者转开胸,最终行胆管切除术并系统淋巴结清扫。患者顺利恢复,术后第5天出院。手术后,患者病理诊断为pT3N2M0(pIIIB)肺腺癌,含有EGFR L858R基因突变,并开始辅助使用伊可替尼。患者在开始使用伊可替尼13个月后出现多发性肺转移,液体活检显示T790M突变;他开始接受第三代EGFR-TKI奥莫替尼治疗。在2025年12月的最后一次随访中,患者继续接受奥莫替尼治疗,并且没有进展。结论:年龄本身不是肺癌手术的禁忌症,八十多岁的患者在仔细的术前评估后可以耐受手术切除。辅助靶向治疗可延长手术后携带致癌驱动基因突变的80多岁肺癌患者的生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer reports
Cancer reports Medicine-Oncology
CiteScore
2.70
自引率
5.90%
发文量
160
审稿时长
17 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书